Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a potentially curative therapy for patients suffering from hematological malignancies via the donor immune system driven graft-versus-leukemia effect. However, the therapy is mainly limited by severe acute and chronic graft-versus-host...
Guardado en:
Autores principales: | Lukas M. Braun, Robert Zeiser |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8e05d6cf6e4145bcafbadad76c11be1c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
por: Joanne E. Davis, et al.
Publicado: (2021) -
Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
por: Daniele Cattaneo, et al.
Publicado: (2021) -
The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review
por: Kamil D. Kaplanov
Publicado: (2021) -
Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
por: Leigh Naylor-Adamson, et al.
Publicado: (2021) -
ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
por: Tatiana E. Bialik, et al.
Publicado: (2021)